Cargando…
Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report
BACKGROUND: Immune checkpoint inhibitors (ICIs) are the standard treatment for metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H). Among immune-related adverse events (irAEs), drug-induced sarcoidosis-like reactions (DISR) are often difficult to differentiate from cance...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365267/ https://www.ncbi.nlm.nih.gov/pubmed/37492584 http://dx.doi.org/10.3389/fimmu.2023.1203621 |
_version_ | 1785077004965511168 |
---|---|
author | Sagawa, Tamotsu Sato, Yasushi Nagashima, Hiroyuki Takada, Kohichi Takahashi, Mamoru Hirakawa, Masahiro Hamaguchi, Kyoko Tamura, Fumito Fujikawa, Koshi Okamoto, Koichi Kawano, Yutaka Sogabe, Masahiro Miyamoto, Hiroshi Takayama, Tetsuji |
author_facet | Sagawa, Tamotsu Sato, Yasushi Nagashima, Hiroyuki Takada, Kohichi Takahashi, Mamoru Hirakawa, Masahiro Hamaguchi, Kyoko Tamura, Fumito Fujikawa, Koshi Okamoto, Koichi Kawano, Yutaka Sogabe, Masahiro Miyamoto, Hiroshi Takayama, Tetsuji |
author_sort | Sagawa, Tamotsu |
collection | PubMed |
description | BACKGROUND: Immune checkpoint inhibitors (ICIs) are the standard treatment for metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H). Among immune-related adverse events (irAEs), drug-induced sarcoidosis-like reactions (DISR) are often difficult to differentiate from cancer progression. MAIN BODY: This is a case of a woman in her mid-60s, with mCRC (RAS wild/BRAF mutant/MSI-H) and abdominal lymph node metastasis, treated with four courses of ipilimumab + nivolumab every 3 weeks, followed by nivolumab every 2 weeks as third-line treatment. After treatment, the original lymph node metastases shrank, but hilar/mediastinal lymph nodes appeared. Endoscopic ultrasound-guided fine-needle aspiration of these lymph nodes revealed multiple epithelioid granulomas without necrosis, indicating a sarcoidosis-like reaction. Fluorodeoxyglucose-positron emission tomography scan showed abnormal subcutaneous accumulation in bilateral forearms and bilateral knee joints. Biopsy of the cutaneous lesions was also performed, which revealed epithelioid granulomas. As the patient had no symptoms in other organs, no specific therapeutic intervention was administered. After the discontinuation of immunotherapy, the sarcoidosis-like reaction regressed without cancer relapse. CONCLUSIONS: Clinicians should be aware of the possibility of DISR as an irAE during the ICI treatment of mCRC. In suspected cases of DISR following ICI therapy, it is important to differentiate between cancer progression and DISR through histological diagnosis for the subsequent strategy, as radiological and serological findings are not definitive. |
format | Online Article Text |
id | pubmed-10365267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103652672023-07-25 Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report Sagawa, Tamotsu Sato, Yasushi Nagashima, Hiroyuki Takada, Kohichi Takahashi, Mamoru Hirakawa, Masahiro Hamaguchi, Kyoko Tamura, Fumito Fujikawa, Koshi Okamoto, Koichi Kawano, Yutaka Sogabe, Masahiro Miyamoto, Hiroshi Takayama, Tetsuji Front Immunol Immunology BACKGROUND: Immune checkpoint inhibitors (ICIs) are the standard treatment for metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H). Among immune-related adverse events (irAEs), drug-induced sarcoidosis-like reactions (DISR) are often difficult to differentiate from cancer progression. MAIN BODY: This is a case of a woman in her mid-60s, with mCRC (RAS wild/BRAF mutant/MSI-H) and abdominal lymph node metastasis, treated with four courses of ipilimumab + nivolumab every 3 weeks, followed by nivolumab every 2 weeks as third-line treatment. After treatment, the original lymph node metastases shrank, but hilar/mediastinal lymph nodes appeared. Endoscopic ultrasound-guided fine-needle aspiration of these lymph nodes revealed multiple epithelioid granulomas without necrosis, indicating a sarcoidosis-like reaction. Fluorodeoxyglucose-positron emission tomography scan showed abnormal subcutaneous accumulation in bilateral forearms and bilateral knee joints. Biopsy of the cutaneous lesions was also performed, which revealed epithelioid granulomas. As the patient had no symptoms in other organs, no specific therapeutic intervention was administered. After the discontinuation of immunotherapy, the sarcoidosis-like reaction regressed without cancer relapse. CONCLUSIONS: Clinicians should be aware of the possibility of DISR as an irAE during the ICI treatment of mCRC. In suspected cases of DISR following ICI therapy, it is important to differentiate between cancer progression and DISR through histological diagnosis for the subsequent strategy, as radiological and serological findings are not definitive. Frontiers Media S.A. 2023-07-10 /pmc/articles/PMC10365267/ /pubmed/37492584 http://dx.doi.org/10.3389/fimmu.2023.1203621 Text en Copyright © 2023 Sagawa, Sato, Nagashima, Takada, Takahashi, Hirakawa, Hamaguchi, Tamura, Fujikawa, Okamoto, Kawano, Sogabe, Miyamoto and Takayama https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Sagawa, Tamotsu Sato, Yasushi Nagashima, Hiroyuki Takada, Kohichi Takahashi, Mamoru Hirakawa, Masahiro Hamaguchi, Kyoko Tamura, Fumito Fujikawa, Koshi Okamoto, Koichi Kawano, Yutaka Sogabe, Masahiro Miyamoto, Hiroshi Takayama, Tetsuji Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report |
title | Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report |
title_full | Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report |
title_fullStr | Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report |
title_full_unstemmed | Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report |
title_short | Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report |
title_sort | hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365267/ https://www.ncbi.nlm.nih.gov/pubmed/37492584 http://dx.doi.org/10.3389/fimmu.2023.1203621 |
work_keys_str_mv | AT sagawatamotsu hilarmediastinalandcutaneousdruginducedsarcoidosislikereactionassociatedwithimmunecheckpointinhibitorsinmetastaticcolorectalcanceracasereport AT satoyasushi hilarmediastinalandcutaneousdruginducedsarcoidosislikereactionassociatedwithimmunecheckpointinhibitorsinmetastaticcolorectalcanceracasereport AT nagashimahiroyuki hilarmediastinalandcutaneousdruginducedsarcoidosislikereactionassociatedwithimmunecheckpointinhibitorsinmetastaticcolorectalcanceracasereport AT takadakohichi hilarmediastinalandcutaneousdruginducedsarcoidosislikereactionassociatedwithimmunecheckpointinhibitorsinmetastaticcolorectalcanceracasereport AT takahashimamoru hilarmediastinalandcutaneousdruginducedsarcoidosislikereactionassociatedwithimmunecheckpointinhibitorsinmetastaticcolorectalcanceracasereport AT hirakawamasahiro hilarmediastinalandcutaneousdruginducedsarcoidosislikereactionassociatedwithimmunecheckpointinhibitorsinmetastaticcolorectalcanceracasereport AT hamaguchikyoko hilarmediastinalandcutaneousdruginducedsarcoidosislikereactionassociatedwithimmunecheckpointinhibitorsinmetastaticcolorectalcanceracasereport AT tamurafumito hilarmediastinalandcutaneousdruginducedsarcoidosislikereactionassociatedwithimmunecheckpointinhibitorsinmetastaticcolorectalcanceracasereport AT fujikawakoshi hilarmediastinalandcutaneousdruginducedsarcoidosislikereactionassociatedwithimmunecheckpointinhibitorsinmetastaticcolorectalcanceracasereport AT okamotokoichi hilarmediastinalandcutaneousdruginducedsarcoidosislikereactionassociatedwithimmunecheckpointinhibitorsinmetastaticcolorectalcanceracasereport AT kawanoyutaka hilarmediastinalandcutaneousdruginducedsarcoidosislikereactionassociatedwithimmunecheckpointinhibitorsinmetastaticcolorectalcanceracasereport AT sogabemasahiro hilarmediastinalandcutaneousdruginducedsarcoidosislikereactionassociatedwithimmunecheckpointinhibitorsinmetastaticcolorectalcanceracasereport AT miyamotohiroshi hilarmediastinalandcutaneousdruginducedsarcoidosislikereactionassociatedwithimmunecheckpointinhibitorsinmetastaticcolorectalcanceracasereport AT takayamatetsuji hilarmediastinalandcutaneousdruginducedsarcoidosislikereactionassociatedwithimmunecheckpointinhibitorsinmetastaticcolorectalcanceracasereport |